In NASH, selectivity for THR-β may provide metabolic benefits of thyroid hormone mediated by the liver, including modulating hepatic steatosis, reducing atherogenic lipids (low-density lipoprotein–cholesterol, triglycerides), and lipoproteins (apolipoprotein B and CIII, lipoprotein[a]), while minimizing systemic sequelae related to excess exogenous thyroid hormone administration, particularly relating to cardiac and bone effects, which are principally mediated via THR-α.24 This evidence concerns the gene TG and fatty liver disease.